Integrating Digital Holographic Microscopy with fluorescence techniques enhances live-cell imaging, preserving cellular ...

NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease ...

Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

Long-term secukinumab treatment may preserve bone structure and support sustained disease control in psoriatic arthritis over 48 months.

The aerospace and defense sector is undergoing rapid material transformation. Additive manufacturing, high-temperature superalloys, advanced aluminum systems, multilayer coatings, and emerging ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company”), a clinical-stage pharmaceutical company developing targeted ...

Engineered nanoparticles built around indocyanine green, a fluorescent dye already approved for clinical use, could sharpen how surgeons see and remove tumors during operations. A study in the journal ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

The Bulls N’ Bears ASX Runner of the Week is… Killi Resources, after a boardroom makeover brought in ex-Fortescue boss Nev ...

The NSF-DOE Vera C. Rubin Observatory has logged more than 11,000 new asteroids from its earliest observations, including 33 ...